Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
E: investor.relations@sanofi.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
markets
Globalisation declining? Not in investor portfolios
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,641.70 | 16.80 | 0.19% |
| CAC 40 | 7,788.10 | 38.69 | -0.49% |
| DAX 40 | 24,038.19 | 188.30 | -0.78% |
| Dow JONES (US) | 42,098.70 | 244.95 | -0.58% |
| FTSE 100 | 8,726.01 | 52.04 | -0.59% |
| HKSE | 23,408.36 | 150.05 | 0.65% |
| NASDAQ | 19,100.94 | 98.22 | -0.51% |
| Nikkei 225 | 38,288.23 | 565.83 | 1.50% |
| NZX 50 Index | 12,283.16 | 79.10 | -0.64% |
| S&P 500 | 5,888.55 | 32.99 | -0.56% |
| S&P/ASX 200 | 8,415.10 | 18.20 | 0.22% |
| SSE Composite Index | 3,363.97 | 24.04 | 0.72% |